Claims for Patent: 10,058,614

Summary for Patent: 10,058,614

Title:	Pharmaceutical compositions comprising meloxicam
Abstract:	Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
Inventor(s):	Herriot Tabuteau
Assignee:	Axsome Therapeutics Inc
Application Number:	US15/797,955
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,058,614
Patent Claims:	1. A dosage form comprising a complex of meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD), and a bicarbonate, wherein the dosage form is an oral dosage form having a shorter Tmax of meloxicam than a reference dosage form that: 1) contains the same amount of meloxicam, 2) does not contain an SBEβCD, and 3) does not contain a bicarbonate. 2. The dosage form of claim 1, containing about 10 mg to about 20 mg of meloxicam. 3. The dosage form of claim 1, containing about 15 mg of meloxicam. 4. The dosage form of claim 1, wherein the SBEβCD has about 6 to about 7 sulfobutyl ether groups for each molecule of β-cyclodextrin. 5. The dosage form of claim 1, containing about 50 mg to about 200 mg of the SBEβCD. 6. The dosage form of claim 1, containing about 100 mg of the SBEβCD. 7. The dosage form of claim 1, wherein the bicarbonate comprises sodium bicarbonate. 8. The dosage form of claim 1, containing about 400 mg to about 600 mg of the bicarbonate. 9. The dosage form of claim 1, containing about 500 mg of sodium bicarbonate. 10. The dosage form of claim 1, further comprising an acid inhibitor. 11. The dosage form of claim 10, wherein the acid inhibitor is a proton pump inhibitor. 12. The dosage form of claim 11, wherein the proton pump inhibitor is esomeprazole. 13. The dosage form of claim 9, wherein about 30 mg to about 50 mg of esomeprazole is present in the dosage form. 14. The dosage form of claim 1, containing about 40 mg of esomeprazole. 15. The dosage form of claim 11, wherein the proton pump inhibitor is esomeprazole, omeprazole, lansoprazole, pantoprazole, or rabeprazole. 16. The dosage form of claim 1, wherein the oral dosage form has been shown to have a Tmax of meloxicam that is less than about 3 hours in an average person. 17. The dosage form of claim 1, wherein the oral dosage form has been shown to have a Tmax of meloxicam that is less than about 2 hours in an average person. 18. The dosage form of claim 1, wherein the oral dosage form has been shown to have a Tmax of meloxicam that is less than about 1 hour in an average person.